Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Prime Medicine, Inc. (NASDAQ: PRME ) is working on leading gene-editing technology, leveraging its proprietary Prime Editing platform. This IP offers one-time therapeutic solutions for conditions with limited or no treatment alternatives. The company’s pipeline includes its leading candidate, PM359, indicated for chronic granulomatousMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree ...